Whole Genome Sequencing Market Forecasts to 2030 - Global Analysis By Product (Consumables, Instruments and Services), Type (Small Whole Genome Sequencing & Large Whole Genome Sequencing), Workflow, Technology, Application, End User and By Geography

According to Stratistics MRC, the Global Whole Genome Sequencing Market is accounted for $45.28 billion in 2023 and is expected to reach $84.51 billion by 2030 growing at a CAGR of 13.5% during the forecast period. Whole Genome Sequencing (WGS) is a comprehensive method used to determine the complete DNA sequence of an organism's genome. The genome is the complete set of DNA, including all of the genes and non-coding regions that carry the genetic information for the development, functioning, and maintenance of an organism. Whole genome sequencing plays a critical role in advancing both research and clinical applications in the field of genomics.

According to the Centers for Disease Control and Prevention statistics, around 1 in every 707 newborn children in the U.S. suffer from Down syndrome, which accounts for approximately 5,568 children in the U.S.

Market Dynamics:

Driver:

Rising prevalence of genetic disorders

WGS is a powerful tool for identifying genetic variations associated with various disorders. As the prevalence of genetic disorders increases, there is a growing need for accurate and comprehensive diagnostic methods. WGS allows for a thorough examination of an individual's entire genome, providing insights into the genetic basis of diseases. It fuels the research efforts to better understand the underlying genetic mechanisms. Further, the rising awareness of the importance of early detection and intervention in managing genetic disorders contributes to the demand for WGS.

Restraint:

Limited clinical utility in certain conditions

In certain medical conditions, especially complex and multifactorial diseases, the genetic basis may not be well-defined or easily actionable. In some cases, the relevance of specific genomic findings to clinical outcomes may not be well-established. This lack of actionable information can limit the clinical utility of WGS, as healthcare providers may struggle to use the genetic data to inform treatment decisions. It also raises ethical concerns about how to handle such conditions. Thereby, it hinders the integration of WGS into clinical practice.

Opportunity:

Increasing adoption in oncology

Whole genome sequencing enables a comprehensive analysis of a patient's genetic makeup, allowing for a better understanding of the molecular drivers of cancer. It helps to identify specific genetic mutations and alterations that drive the growth of cancer cells. The use of WGS data in oncology research is instrumental in the identification of suitable candidates for clinical trials. As more clinical evidence is generated, and the technology becomes more accessible and cost-effective, the adoption of WGS in oncology is likely to continue its upward trajectory, driving market expansion.

Threat:

Data privacy & security concerns

Genomic data is highly sensitive and contains information about an individual's unique genetic makeup, predispositions to diseases, and potentially other personal traits. The risk of unauthorized access to genomic data raises concerns about the misuse of sensitive information. If genomic data falls into the wrong hands, it could be exploited for various purposes, including identity theft, insurance discrimination, or other malicious activities. Failure to adequately address these concerns can impede the growth of the whole genome sequencing market.

COVID-19 Impact

The covid pandemic had a neutral effect on the whole genome sequencing market. The pandemic highlighted the role that genetics plays in comprehending and preventing infectious illnesses. Whole genome sequencing has been used by researchers all around the world to examine the genetic composition and evolutionary history of the SARS-CoV-2 virus. This lightened the significance of genetics in personalized treatment. On the other hand, the market was momentarily impacted by variables including the interruption of supply networks and changes in research objectives.

The precision medicine segment is expected to be the largest during the forecast period

The precision medicine segment is estimated to have a lucrative. Precision medicine involves tailoring medical treatment and healthcare decisions to the individual characteristics of each patient. Whole genome sequencing plays a central role in precision medicine, providing a comprehensive analysis of an individual's entire genome. It helps to optimize drug selection and dosage. Additionally, it offers cost effective treatments, patient empowerment and personalized care plans which accelerates the segment growth.

The research centers segment is expected to have the highest CAGR during the forecast period

The research centers segment is anticipated to witness the highest CAGR growth during the forecast period, due to the advancements in a wide range of research fields. WGS offers a myriad of uses and benefits in research centers, contributing to the significant understanding of genetics, genomics, and various biological processes. It also provides critical information for understanding disease mechanisms, identifying potential therapeutic targets, and developing personalized treatment approaches.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the growing investment in R&D activities. The Asia-Pacific region has experienced substantial growth in the biotechnology and healthcare sectors. Governments have initiated funding programs and supportive policies to encourage the adoption of genomic technologies for research and clinical applications. The region's diverse population along with growing generic disorders is boosting the market's expansion.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the rising government funding. The region hosts numerous leading biotechnology & pharmaceutical companies focused on genomics and personalized medicine. Consumers in North America have shown interest in learning about their ancestry, predisposition to certain health conditions, and other genomic information. Further, the rising innovation in whole genome sequencing and its application in cancer treatments are thereby augmenting the regional market trends.

Key players in the market:

Some of the key players profiled in the Whole Genome Sequencing Market include Siemens Healthineers, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Danaher Corporation, Agilent Technologies Inc, Illumina Inc, Complete Genomics, QIAGEN N.V., GeneDx, Merck KGaA, Abbott, Eurofins Scientific, Oxford Nanopore Technologies, Bio-Rad Laboratories, Inc and Macrogens Inc.

Key Developments:

In October 2023, Oxford Nanopore Technologies and Fabric Genomics collaborated to launch an integrated whole-genome sequencing solution to advance the future of paediatric patient care. The joint solution, which will be commercially available for deployment in CLIA/CAP labs, will support use of nanopore sequencing in neonatal/pediatric intensive care units.

In October 2023, Complete Genomics, a pioneering genomic sequencing company, launched its DNBSEQ-T20x2* product, which reduced the cost of whole genome sequencing to less than $100 per 30X WGS.

In August 2023, GeneDx and PacBio announced research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.

Products Covered:

• Consumables
• Instruments
• Services

Types Covered:

• Small Whole Genome Sequencing
• Large Whole Genome Sequencing

Workflows Covered:

• Data Analysis
• Sequencing
• Pre-Sequencing

Technologies Covered:

• Sanger Sequencing
• Microarray
• Polymerase Chain Reaction
• Next Generation Sequencing
• Other Technologies

Applications Covered:

• Drug Discovery & Development
• Diagnostics
• Precision Medicine
• Other Applications

End Users Covered:

• Academic Institutes
• Hospitals & Clinics
• Research Centers
• Pharmaceutical & Biotechnology Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances